Free tool
FAERS Monitor: Furadantin
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 009175 or its brand name (Furadantin, Nitrofurantoin). Reports on generic versions are filed under their own applications.
Reports
16,747
Serious
13,463
80% of reports
Hospitalization
5,733
Death reported
1,040
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- urinary tract infection1,399
- fatigue1,291
- nausea1,238
- headache1,161
- pain1,009
- dyspnoea1,001
- diarrhoea913
- rash890
- malaise866
- vomiting854
- pyrexia830
- dizziness820
- drug ineffective807
- off label use753
- fall608
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2004 | 90 |
| 2005 | 108 |
| 2006 | 118 |
| 2007 | 105 |
| 2008 | 139 |
| 2009 | 203 |
| 2010 | 284 |
| 2011 | 341 |
| 2012 | 540 |
| 2013 | 513 |
| 2014 | 545 |
| 2015 | 742 |
| 2016 | 972 |
| 2017 | 857 |
| 2018 | 1,200 |
| 2019 | 1,521 |
| 2020 | 1,343 |
| 2021 | 1,322 |
| 2022 | 1,282 |
| 2023 | 1,240 |
| 2024 | 1,152 |
| 2025 | 1,193 |
| 2026 | 937 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,037,412 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| urinary tract infectionSignal | 1,399 | 10.4 | 9.9 | 11,844 |
| pyrexiaSignal | 830 | 3.0 | 2.8 | 1,134 |
| rashSignal | 890 | 2.6 | 2.4 | 866 |
| malaiseSignal | 866 | 2.5 | 2.3 | 780 |
| headacheSignal | 1,161 | 2.3 | 2.2 | 904 |
| fallSignal | 608 | 2.3 | 2.1 | 450 |
| vomitingSignal | 854 | 2.3 | 2.1 | 628 |
| dyspnoeaSignal | 1,001 | 2.2 | 2.1 | 690 |
| fatigueSignal | 1,291 | 2.1 | 2.0 | 754 |
| dizzinessSignal | 820 | 2.1 | 1.9 | 460 |
| painSignal | 1,009 | 2.1 | 1.9 | 569 |
| nausea | 1,238 | 2.0 | 1.9 | 609 |
| diarrhoea | 913 | 1.8 | 1.7 | 319 |
| off label use | 753 | 1.1 | 1.0 | 5 |
| drug ineffective | 807 | 0.8 | 0.7 | 60 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.